Search Results
Feb 11, 2026, 08:30 ET Secure Cryogenic Transport with Novel Approaches for Preventing Blood Bag Breakage, Upcoming Webinar Hosted by Xtalks
valuable materials.TORONTO, Feb. 11, 2026 /PRNewswire/ -- As cell and gene therapies scale globally, maintaining the integrity of cryopreserved biomaterials during transit is critical. Yet package failure, leakage events and
More news about: Xtalks
Feb 11, 2026, 06:07 ET Molecule Found to Drive Skin Cancer Growth and Evade Immune Detection
drugsNEW YORK, Feb. 11, 2026 /PRNewswire/ -- A molecule that helps regulate gene activity has also been shown to drive skin cancer growth and tumors' ability to evade attack by the body's immune system, a new study shows.
More news about: NYU Langone Health System
Feb 11, 2026, 04:00 ET ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging
noted China's unique strengths in clinical speed, platform iteration and portfolio strategy, predicting globally competitive ADC, TCE and novel cell/gene therapy innovations in the coming years.Cardio-Renal-Metabolic Session:Experts stressed de-risking clinical trials, affirming small
More news about: ACROBiosystems Group
Feb 11, 2026, 01:34 ET Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
2026.Imlifidase in Gene therapy: Initial data from the first patient in the GNT-018-IDES trial, presented at the European Society of Gene and Cell Therapy, showed that imlifidase rapidly and effectively removed AAV antibodies and can potentially serve as a pre-treatment to enable gene therapy in patients
More news about: Hansa Biopharma AB
Feb 11, 2026, 01:29 ET Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
2026.Imlifidase in Gene therapy: Initial data from the first patient in the GNT-018-IDES trial, presented at the European Society of Gene and Cell Therapy, showed that imlifidase rapidly and effectively removed AAV antibodies and can potentially serve as a pre-treatment to enable gene therapy in patients
More news about: Hansa Biopharma AB
Feb 10, 2026, 11:58 ET Regenerative Medicine Market to Reach $531.7 billion, Globally, by 2033 at 32.4% CAGR: Allied Market Research
Regenerative Medicine Market by Product Type (Cell Therapy, Gene Therapy, Tissue Engineering and Small Molecule & Biologic), Material (Synthetic Material, Biologically Derived Material, Genetically Engineered
More news about: Allied Market Research
Feb 10, 2026, 11:17 ET Made Scientific and Streamline Bio Launch Exclusive Early Adopter Program to Advance AI-Driven Robotic Automation for Cell Therapy Manufacturing
Ph.D., President & CEO of Streamline Bio. "By partnering with Made Scientific as our exclusive early adopter CDMO, we are accelerating our cell and gene therapy product development roadmap and building toward a safe, compliant, and cost-effective manufacturing solution that supports the entire life science
More news about: Made Scientific, Inc.
Feb 10, 2026, 11:06 ET When patients lead: Breaking barriers in ultra-rare disease drug development, Upcoming Webinar Hosted by Xtalks
pathways. Through firsthand case studies, patient and parent leaders will share how advocacy-driven initiatives have accelerated gene-targeted therapies, enabled first-in-human treatments and contributed to historic regulatory approvals. The session will examine how these efforts have
More news about: Xtalks
Feb 10, 2026, 09:00 ET DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY
weight and survival, followed by comprehensive lung assessment. Fibrotic burden was evaluated through lung weight, collagen content, fibrosis-related gene expression, and histopathological scoring. In this bleomycin-induced pulmonary fibrosis model, Thykamine™ demonstrated statistically significant
More news about: Devonian Health Group Inc.
Feb 10, 2026, 09:00 ET Supreme Group Adds Science-First Creative Power with Acquisition of Broth
campaigns that resonate with healthcare professionals, patients, and key decision-makers. They offer deep expertise in complex therapeutic areas, including gene therapy, hematology/oncology, immunology, and rare disease with a strength in early positioning, launch strategy, and pre-clinical storytelling.The
More news about: Supreme Group
Feb 10, 2026, 08:30 ET Hudson Valley Property Group Acquires Two Affordable Housing Properties in Boston, Massachusetts
more than 16,300 units nationwide.SVN Affordable | Levental Realty was the exclusive listing broker for the seller and Jamie Renzenbrink and Gene Levental led the transaction on behalf of the firm."It was a privilege to represent the seller's interest in this transaction, and after multiple
More news about: Hudson Valley Property Group
Feb 10, 2026, 08:30 ET Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model
builds on prior research showing GDNF's protective role against diet-induced obesity. Future analyses will include liver pathology, lipid content, and gene/protein expression to further elucidate mechanisms. Hoth plans to accelerate GDNF toward IND-enabling studies, targeting clinical trials in 2027.
More news about: Hoth Therapeutics, Inc.
Feb 10, 2026, 08:09 ET Iterion Therapeutics Announces First Patient Dosed in Clinical Study of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, in Relapsed/Refractory Osteosarcoma
selectively disrupting the TBL1/β-catenin transcriptional complex, tegavivint promotes degradation of nuclear β-catenin and suppresses β-catenin-dependent gene transcription, shutting down Wnt-driven tumor growth while avoiding the dose-limiting toxicities historically associated with upstream Wnt inhibition."Tegavivint
More news about: Iterion Therapeutics
Feb 10, 2026, 08:07 ET On Site: "2026 China Forum on Source Innovation in New Drug Discovery" Concludes Successfully
pipeline quality has improved significantly, with a rising proportion of First-in-Class (FIC) assets, particularly in advanced therapies such as cell and gene therapies (CGT) and nucleic acid-based drugs.Although global and Chinese biotech investment and financing activity in innovative drugs has experienced
More news about: Sanyou Bio
Feb 10, 2026, 08:00 ET Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex
More news about: Genprex, Inc.
Feb 10, 2026, 08:00 ET Vanscoy Rare Pharmacy Selected as Exclusive Distribution Pharmacy for Redemplo® (plozasiran) for adults with Familial Chylomicronemia Syndrome (FCS)
is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.For more information, visit
More news about: Vanscoy Rare Pharmacy
Feb 10, 2026, 06:47 ET Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share
innovations to our Advanced Diagnostics portfolio, including a new Quest AD-Detect® blood test for aiding the diagnosis of Alzheimer's disease, long-read gene sequencing to identify the cause of ataxia movement disorders, and HPV self-collection options for cervical cancer screening. Secured FDA breakthrough
More news about: Quest Diagnostics
Feb 09, 2026, 17:55 ET CleanSpace Appoints Shelley Preslar as Vice President of Quality for CleanShield Division
decree remediation efforts, supporting fast-track facility startups, and implementing global quality systems across pharmaceutical, biotech, cell and gene therapy, and compounding operations."Shelley's expertise is a critical addition to how we support clients across the full arc of facility delivery,"
More news about: CleanSpace Modular, LLC
Feb 09, 2026, 16:05 ET REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II
(clemidsogene lanparvovec)RGX-121 is a potential one-time gene therapy for the treatment of boys with MPS II, designed to deliver the iduronate-2-sulfatase (IDS) gene to the CNS. Delivery of the IDS gene within cells in the CNS could provide a permanent source of secreted iduronate-2-sulfatase
More news about: REGENXBIO Inc.
Feb 09, 2026, 08:18 ET EQT Life Sciences co-leads USD 39 million Series A in Aerska to help systematically deliver RNA medicines to the brain
delivery approach is designed to enable intravenous or subcutaneous administration, achieving uniform and deep brain distribution with durable target gene knockdown, unlocking new therapeutic possibilities for neurological diseases.Jack O'Meara, CEO & Co-Founder, Aerska, said: "The ability to
More news about: EQT
Feb 09, 2026, 08:16 ET EQT Life Sciences co-leads USD 39 million Series A in Aerska to help systematically deliver RNA medicines to the brain
delivery approach is designed to enable intravenous or subcutaneous administration, achieving uniform and deep brain distribution with durable target gene knockdown, unlocking new therapeutic possibilities for neurological diseases.Jack O'Meara, CEO & Co-Founder, Aerska, said: "The ability to
More news about: EQT
Feb 09, 2026, 08:00 ET DIFF Biotech's Innovative Nasal Spray Influenza Vaccine Receives Clinical Trial Approval, Introducing a New Attenuation Pathway
drugs, oncolytic viruses, and gene therapy products. Its vaccine pipeline—powered by proprietary attenuation technologies—effectively establishes the body's first line of defense at the mucosal barrier, offering clear competitive differentiation. In the oncolytic virus and gene therapy domains, DIFF Biotech
More news about: DIFF Biotech
Feb 09, 2026, 08:00 ET Unchained Labs Explodes into AI-Driven Automation, Launches Stuntman
power they need — all while keeping AI in the loop."About Unchained LabsHere's the deal. We're all about helping biologics and gene therapy researchers break free from tools that just don't cut it. Unleashing problem-tackling solutions and AI-driven automation that make a huge difference
More news about: Unchained Labs
Feb 09, 2026, 08:00 ET Unchained Labs Explodes into AI-Driven Automation, Launches Stuntman
power they need — all while keeping AI in the loop."About Unchained LabsHere's the deal. We're all about helping biologics and gene therapy researchers break free from tools that just don't cut it. Unleashing problem-tackling solutions and AI-driven automation that make a huge difference
More news about: Unchained Labs
Feb 09, 2026, 03:12 ET Diamyd Medical receives Notice of Allowance for key retogatein US patent
antigen-specific immune tolerance to GAD65 and preserve endogenous insulin production in individuals with type 1 diabetes who carry the HLA DR3-DQ2 gene. Retogatein has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 3 (clinically
More news about: Diamyd Medical AB